Flip flop policy over pioglitazone licence causes media storm in IndiaBMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4937 (Published 06 August 2013) Cite this as: BMJ 2013;347:f4937
- Soumyadeep Bhaumik
India’s ministry of health and family welfare has revoked the ban that it placed on the antidiabetes drug pioglitazone just six weeks ago because of the drug’s association with bladder cancer.1
The Drug Technical Advisory Board, through the Gazette of India, recommended revoking the ban after reviewing the evidence, and imposed various conditions for the use of pioglitazone.2 It recommends, for example, that pioglitazone should not be used as a first line treatment for diabetes.
The ban and the subsequent reversal of the policy have caused a media storm in India, …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial